# Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer

> **NCT02085005** · PHASE2 · WITHDRAWN · sponsor: **Sanofi**

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Aflibercept AVE0005
- **DRUG:** Oxaliplatin SR96669

## Key facts

- **NCT ID:** NCT02085005
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-03
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02085005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02085005, "Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT02085005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*